Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Argus Health
Johnson and Johnson
Mallinckrodt
Baxter
Federal Trade Commission
McKinsey
Colorcon
Covington

Generated: September 21, 2018

DrugPatentWatch Database Preview

Abraxis Bioscience Company Profile

« Back to Dashboard

What is the competitive landscape for ABRAXIS BIOSCIENCE, and when can generic versions of ABRAXIS BIOSCIENCE drugs launch?

ABRAXIS BIOSCIENCE has one approved drug.

There are twelve US patents protecting ABRAXIS BIOSCIENCE drugs.

Summary for Abraxis Bioscience

Drugs and US Patents for Abraxis Bioscience

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abraxis Bioscience ABRAXANE paclitaxel FOR SUSPENSION;IV (INFUSION) 021660-001 Jan 7, 2005 RX Yes Yes 8,853,260 ➤ Sign Up Y ➤ Sign Up
Abraxis Bioscience ABRAXANE paclitaxel FOR SUSPENSION;IV (INFUSION) 021660-001 Jan 7, 2005 RX Yes Yes 8,138,229 ➤ Sign Up Y ➤ Sign Up
Abraxis Bioscience ABRAXANE paclitaxel FOR SUSPENSION;IV (INFUSION) 021660-001 Jan 7, 2005 RX Yes Yes 7,758,891 ➤ Sign Up ➤ Sign Up
Abraxis Bioscience ABRAXANE paclitaxel FOR SUSPENSION;IV (INFUSION) 021660-001 Jan 7, 2005 RX Yes Yes 9,597,409 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Abraxis Bioscience

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abraxis Bioscience ABRAXANE paclitaxel FOR SUSPENSION;IV (INFUSION) 021660-001 Jan 7, 2005 5,439,686 ➤ Sign Up
Abraxis Bioscience ABRAXANE paclitaxel FOR SUSPENSION;IV (INFUSION) 021660-001 Jan 7, 2005 6,537,579 ➤ Sign Up
Abraxis Bioscience ABRAXANE paclitaxel FOR SUSPENSION;IV (INFUSION) 021660-001 Jan 7, 2005 6,506,405 ➤ Sign Up
Abraxis Bioscience ABRAXANE paclitaxel FOR SUSPENSION;IV (INFUSION) 021660-001 Jan 7, 2005 6,096,331 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for ABRAXIS BIOSCIENCE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe For Injection Suspension 100 mg/vial ➤ Subscribe 2015-12-11

Non-Orange Book US Patents for Abraxis Bioscience

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,537,579 Compositions and methods for administration of pharmacologically active compounds ➤ Sign Up
5,916,596 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof ➤ Sign Up
5,512,268 Polymeric shells for medical imaging prepared from synthetic polymers, and methods for the use thereof ➤ Sign Up
5,560,933 Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for Abraxis Bioscience Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0961612/01 Switzerland ➤ Sign Up PRODUCT NAME: PACLITAXELUM-ALBUMINUM; REGISTRATION NO/DATE: SWISSMEDIC 63182 26.08.2014
8 50005-2014 Slovakia ➤ Sign Up PRODUCT NAME: PAKLITAXEL VO FORME NANOCASTIC VIAZANYCH NA ALBUMIN; REGISTRATION NO/DATE: EU/1/07/428/001 - EU/1/07/428/002 20131230
0673 Netherlands ➤ Sign Up PRODUCT NAME: PACLITAXEL, GEFORMULEERD ALS ALBUMINE-GEBONDEN NANODEELTJES; REGISTRATION NO/DATE: EU/1/07/428/001-002 20131220
/2014 Austria ➤ Sign Up PRODUCT NAME: PACLITAXEL, DAS ALS ALBUMIN GEBUNDENE NANOPARTIKEL FORMUIERT IST.; REGISTRATION NO/DATE: EU/1/07/428 (MITTEILUNG) (GEAENDERT DURCH C(2013) 9835) 20131230
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Julphar
Chinese Patent Office
Merck
Citi
QuintilesIMS
Fuji
Deloitte
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.